Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD
Earnings Data
Report Date
Nov 11, 2025After Close (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
0.14Last Year’s EPS
0.2Same Quarter Last Year
Moderate Buy
Based on 18 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment overall, with strong financial performance, significant growth in DAYBUE and NUPLAZID sales, and a robust pipeline expansion. However, increased SG&A expenses and challenges in clinical trials were noted as areas of concern.Company Guidance
Strong Financial Performance
ACADIA achieved total revenue of $264.6 million for the quarter, marking a 9% year-over-year increase.
DAYBUE Growth
DAYBUE net product sales reached $96.1 million, up 14% from the previous year, with a steady increase in patient uptake.
NUPLAZID Performance
NUPLAZID sales were $168.5 million, a 7% year-over-year increase, driven by a 17% rise in referrals and successful direct-to-consumer campaigns.
Pipeline Expansion
9 disclosed programs in development with 5 Phase II or III data readouts expected through 2027. Notable programs include ACP-211 for major depressive disorder and ACP-271 for tardive dyskinesia and Huntington's disease.
Increased Cash Balance
Cash balance increased to $762 million, from $756 million at the end of 2024.
ACAD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ACAD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 06, 2025 | $23.80 | $24.40 | +2.52% |
May 07, 2025 | $14.81 | $16.93 | +14.31% |
Feb 26, 2025 | $19.00 | $19.34 | +1.79% |
Nov 06, 2024 | $15.79 | $17.20 | +8.93% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does ACADIA Pharmaceuticals (ACAD) report earnings?
ACADIA Pharmaceuticals (ACAD) is schdueled to report earning on Nov 11, 2025, After Close (Confirmed).
What is ACADIA Pharmaceuticals (ACAD) earnings time?
ACADIA Pharmaceuticals (ACAD) earnings time is at Nov 11, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ACAD EPS forecast?
ACAD EPS forecast for the fiscal quarter 2025 (Q3) is 0.14.